Print

RXi Pharmaceuticals (RXII) to Present at 15th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference  
2/4/2013 6:12:48 AM

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company’s President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 15th Annual BIO CEO & Investor Conference on Monday, February 11th at 4:00pm ET. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi’s sd-rxRNA® technology platform.
//-->